Generally speaking, anti‐tau antibodies targeting the mid‐region of tau proved to be most effective against human tau pathologic seeds (from AD and PSP) than those targeting the N‐terminus region (Courade et al. 2018). The gene discussed is MAPT; the disease is Alzheimer disease.